What we’re funding

The Australian Government is investing $35 million to fund proof-of-concept to commercial development of biomedical and medical technologies (biomedtech). This funding is being administered by MTPConnect, the Medical Technology and Pharmaceutical Industry Growth Centre.  

Desired outcomes

The purpose of this research funding is to:

  • develop new medical innovation and technology in Australia to benefit Australians
  • grow our biomedtech sector so that Australia’s world-class research is developed into real treatments, drugs and devices
  • boost employment and  grow business in the biomedtech sector.

Key elements

The BioMedTech Horizons provides funding to innovative health and medical innovation researchers and startups to turn discoveries into reality.

$10 million in projects are already being funded, including:

  • the ‘BioPen’, a handheld 3D printer that can be used in surgery to repair damaged cartilage
  • the world’s first rapid diagnostic test for the pathogens that causes sepsis
  • a fully synthetic 3D printed spinal cage.

The program will increase the number of biomedical and medical technology ideas that have the potential to create better health outcomes for Australians and stimulate new jobs and business growth.

Why it's important

  • BioMedTech Horizons provides new avenue for talented Australians to move ideas out of the lab and into the clinic.
  • Ground breaking biological and medical technologies have a significant place in the future of healthcare.
  • Financial barriers make it difficult to transform innovative ideas into new technologies. This program will allow researchers and entrepreneurs to break through these barriers.
  • Patients will have access to cutting edge therapies and innovation in healthcare through concerted research efforts and investment.
  • Australian businesses will be supported to develop technologies from proof of concept to commercial success.

How to apply

Applications for this program are currently closed.

Last updated: 
7 May 2018